神経変性疾患治療薬の世界市場レポート 2024

神経変性疾患治療薬の市場規模は、今後数年間で大幅に成長すると予想されます。 2028年には9.0%の年間複合成長率（CAGR）で283億3,000万米ドルに成長すると予想されます。予測期間で予想される成長は、利用可能な臨床試験とヘルスケア支出の増加に加えて、個別化医療と標的療法に対する需要の増加など、いくつかの要因によって推進されます。この期間中に予想される重要な動向には、疾患修飾治療、非薬理学的介入、遠隔医療と遠隔モニタリングの統合、継続的な技術進歩、精密ベースの治療法、デジタルヘルスソリューション、バイオマーカー主導型試験の実施などが含まれます。

神経変性疾患の世界の発生拡大により、神経変性疾患治療薬市場の成長が促進されています。神経変性疾患の増加は、高齢者人口の増加と密接に関係しています。世界人口予測によれば、60歳以上の高齢者は2050年までに21億人に達し、80歳以上の人口は3倍の4億2,500万人に達すると予想されています。アルツハイマー病協会の報告書によると、現在約580万人のアメリカ人がアルツハイマー病に苦しんでおり、2050年までに約1,400万人に急増すると予測されています。この高齢化人口統計における有病率の高まりにより、治療薬の需要が高まり、その結果神経変性疾患治療薬市場が推進されています。

神経変性疾患治療薬市場で予想される成長は、研究開発（R&D）への投資の増加によって支えられています。政府や組織は、有病率の上昇、満たされていない医療ニーズ、経済的影響、世界の健康への取り組みなど、さまざまなやむを得ない理由により、神経変性疾患の調査に多大なリソースを注ぎ込んでいます。たとえば、2021年 10月の時点で、PhRMAは、29の神経変性疾患に対する開発パイプラインで260以上の進行中の薬剤を報告しました。さらに、約100万人のアメリカ人が罹患しているパーキンソン病に対して64種類の治療薬が開発されており、2030年までに120万人に増加すると予想されています。この研究開発への投資の強化により、神経変性疾患治療薬市場の成長を維持する態勢が整っています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の神経変性疾患治療薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• パーキンソン病
• アルツハイマー病
• 多発性硬化症
• ハンチントン病
• その他の適応症タイプ
• 世界の神経変性疾患治療薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• N-メチル-D-アスパラギン酸受容体
• 選択的セロトニン再取り込み阻害剤
• ドーパミン阻害剤
• その他の薬剤タイプ
• 世界の神経変性疾患治療薬市場、流通別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域および国の分析

• 世界の神経変性疾患治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の神経変性疾患治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経変性疾患治療薬市場の競合情勢
• 神経変性疾患治療薬市場の企業プロファイル
  • Biogen Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Neurodegenerative disorder therapeutics encompass medications or gene therapies designed to therapeutically address patients with neurodegenerative disorders. These aim to directly address underlying disease pathways, focusing on neuroprotection, neurorestoration, and managing symptoms.

The primary drug categories within neurodegenerative disorder therapeutics include N-methyl-D-aspartate receptor drugs, selective serotonin reuptake inhibitors, dopamine inhibitors, and other classes. Selective serotonin reuptake inhibitors, commonly used in treating depression and certain mental illnesses, have diverse applications across conditions such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and other related indications. These medications are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $18.53 billion in 2023 to $20.04 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth observed in the historical period can be credited to several factors, including an aging population, an uptick in the occurrence of neurodegenerative disorders, longer life expectancies, increased investments from pharmaceutical companies, and heightened awareness and advocacy efforts.

The neurodegenerative disorder therapeutics market size is expected to see strongly grown in the next few years. It will grow to $28.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. Anticipated growth in the forecast period is driven by several factors, notably the increasing demand for personalized medicine and targeted therapy, alongside a rise in available clinical trials and healthcare spending. Significant trends expected during this period encompass disease-modifying treatments, non-pharmacological interventions, the integration of telemedicine and remote monitoring, ongoing technological advancements, precision-based therapeutics, digital health solutions, and the implementation of biomarker-driven trials.

The expanding occurrence of neurodegenerative disorders globally drives the growth of the market for neurodegenerative disorder therapeutics. The rise in neurodegenerative conditions is closely linked to the increasing elderly population. As per World Population Prospects, the elderly, aged 60 and above, will reach 2.1 billion by 2050, with the number of individuals over 80 years old tripling to 425 million. Reports from the Alzheimer's Association reveal that currently, around 5.8 million Americans suffer from Alzheimer's disease, projected to surge to approximately 14 million by 2050. This heightened prevalence within aging demographics elevates the demand for therapeutics, consequently propelling the neurodegenerative disorder therapeutics market.

Anticipated growth in the neurodegenerative disorder therapeutics market is underpinned by increased investments in research and development (R&D). Governments and organizations are channeling substantial resources into neurodegenerative disorder research due to various compelling reasons, including rising prevalence, significant unmet medical needs, economic implications, and global health initiatives. For instance, as of October 2021, PhRMA reported over 260 ongoing medications in the development pipeline for 29 neurodegenerative diseases. Additionally, there are 64 medications being developed for Parkinson's disease, a condition affecting nearly one million Americans, with expected growth to 1.2 million by 2030. This augmented investment in R&D is poised to sustain growth in the neurodegenerative disorder therapeutics market.

Manufacturers of neurodegenerative disorder therapeutics are forging strategic partnerships with governmental and non-governmental entities to advance therapeutic solutions for various neurodegenerative diseases. Collaboration among market players is intensifying to bolster research and development capabilities, aiming to innovate new and more efficacious treatments for these disorders. For instance, in July 2022, UK-based NRG Therapeutics partnered with Domainex to jointly develop novel small molecule disease-modifying medications targeting Parkinson's disease, motor neurone disease (MND), and other chronic neurodegenerative conditions.

Key players in the neurodegenerative disorder therapeutics market are leveraging innovative techniques, such as the Neurofilament Light Chain (NfL) blood test, to gain a competitive edge. This test enables medical professionals to detect and confirm signs of neurodegenerative disorders, enhancing diagnostic accuracy and treatment planning. Labcorp, a US-based company, introduced the Neurofilament Light Chain (NfL) blood test in July 2022, allowing for direct evidence of neuronal damage. Elevated NfL levels serve as indicators of neuronal damage caused by conditions like multiple sclerosis, Alzheimer's, Parkinson's disease, or brain injuries such as concussions. NfL, a neuron-specific protein, is a non-specific biomarker for various neurodegenerative conditions like Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), released in response to neuronal injury and neurodegeneration.

In January 2022, VitalPath, a US-based manufacturer of catheters and catheter shafts acquired Modern Catheter Technologies for an undisclosed amount. The acquisition will increase VitalPath's capacity for growth, bringing its entire manufacturing footprint to more than 80,000 square feet, including 35,000 square feet of ISO 7 and 8 cleanroom space. Modern Catheter Technologies is a US-based manufacturer of microcatheters used in neurovascular and electrophysiology.

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca PLC, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2023. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurodegenerative Disorder Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurodegenerative disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurodegenerative disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurodegenerative disorder therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Indication Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Other Indication Types
• 2) By Drug Type: N- methyl- D- aspartate Receptor; Selective Serotonin Reuptake Inhibitor; Dopamine Inhibitors; Other Drug Types
• 3) By Distribution: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Companies Mentioned: Biogen Inc.; Pfizer Inc.; Novartis International AG; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurodegenerative Disorder Therapeutics Market Characteristics

3. Neurodegenerative Disorder Therapeutics Market Trends And Strategies

4. Neurodegenerative Disorder Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Neurodegenerative Disorder Therapeutics Market Size and Growth

• 5.1. Global Neurodegenerative Disorder Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Neurodegenerative Disorder Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Neurodegenerative Disorder Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neurodegenerative Disorder Therapeutics Market Segmentation

• 6.1. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Parkinson's Disease
• Alzheimer's Disease
• Multiple Sclerosis
• Huntington Disease
• Other Indication Types
• 6.2. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• N- methyl- D- aspartate Receptor
• Selective Serotonin Reuptake Inhibitor
• Dopamine Inhibitors
• Other Drug Types
• 6.3. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

7. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis

• 7.1. Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neurodegenerative Disorder Therapeutics Market

• 8.1. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neurodegenerative Disorder Therapeutics Market

• 9.1. China Neurodegenerative Disorder Therapeutics Market Overview
• 9.2. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neurodegenerative Disorder Therapeutics Market

• 10.1. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neurodegenerative Disorder Therapeutics Market

• 11.1. Japan Neurodegenerative Disorder Therapeutics Market Overview
• 11.2. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neurodegenerative Disorder Therapeutics Market

• 12.1. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neurodegenerative Disorder Therapeutics Market

• 13.1. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neurodegenerative Disorder Therapeutics Market

• 14.1. South Korea Neurodegenerative Disorder Therapeutics Market Overview
• 14.2. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neurodegenerative Disorder Therapeutics Market

• 15.1. Western Europe Neurodegenerative Disorder Therapeutics Market Overview
• 15.2. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neurodegenerative Disorder Therapeutics Market

• 16.1. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neurodegenerative Disorder Therapeutics Market

• 17.1. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neurodegenerative Disorder Therapeutics Market

• 18.1. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neurodegenerative Disorder Therapeutics Market

• 19.1. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neurodegenerative Disorder Therapeutics Market

• 20.1. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neurodegenerative Disorder Therapeutics Market

• 21.1. Eastern Europe Neurodegenerative Disorder Therapeutics Market Overview
• 21.2. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neurodegenerative Disorder Therapeutics Market

• 22.1. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neurodegenerative Disorder Therapeutics Market

• 23.1. North America Neurodegenerative Disorder Therapeutics Market Overview
• 23.2. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neurodegenerative Disorder Therapeutics Market

• 24.1. USA Neurodegenerative Disorder Therapeutics Market Overview
• 24.2. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neurodegenerative Disorder Therapeutics Market

• 25.1. Canada Neurodegenerative Disorder Therapeutics Market Overview
• 25.2. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neurodegenerative Disorder Therapeutics Market

• 26.1. South America Neurodegenerative Disorder Therapeutics Market Overview
• 26.2. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neurodegenerative Disorder Therapeutics Market

• 27.1. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neurodegenerative Disorder Therapeutics Market

• 28.1. Middle East Neurodegenerative Disorder Therapeutics Market Overview
• 28.2. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neurodegenerative Disorder Therapeutics Market

• 29.1. Africa Neurodegenerative Disorder Therapeutics Market Overview
• 29.2. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Neurodegenerative Disorder Therapeutics Market Competitive Landscape
• 30.2. Neurodegenerative Disorder Therapeutics Market Company Profiles
  • 30.2.1. Biogen Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis International AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi S.A.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Teva Pharmaceutical Industries Ltd
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Neurodegenerative Disorder Therapeutics Market Competitive Benchmarking

32. Global Neurodegenerative Disorder Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market

34. Neurodegenerative Disorder Therapeutics Market Future Outlook and Potential Analysis

• 34.1 Neurodegenerative Disorder Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Neurodegenerative Disorder Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Neurodegenerative Disorder Therapeutics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer